We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+4.96%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.51B
AUM Growth
+$152M
(+11%)
Cap. Flow
+$148M
Cap. Flow
% of AUM
9.78%
Top 10 Holdings %
Top 10 Hldgs %
81.92%
Holding
39
New
5
Increased
6
Reduced
16
Closed
4
Top Buys
| 1 |
Scholar Rock
SRRK
|
+$172M |
| 2 |
Annexon
ANNX
|
+$25.3M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$10.1M |
| 4 |
ALX Oncology
ALXO
|
+$8.95M |
| 5 |
Prime Medicine
PRME
|
+$6.05M |
Top Sells
| 1 |
RAPT
RAPT Therapeutics
RAPT
|
+$30M |
| 2 |
Cogent Biosciences
COGT
|
+$27.7M |
| 3 |
Replimune Group
REPL
|
+$10.7M |
| 4 |
IDEAYA Biosciences
IDYA
|
+$7.41M |
| 5 |
Nurix Therapeutics
NRIX
|
+$5.99M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$6.46B
| $446M | 29.51% |
9,066,621
+3,845,775
| +74% | +$172M |
|
2
Krystal Biotech
KRYS
$10.1B
| $174M | 11.52% |
673,505
-4,200
| -0.6% | -$1.12M |
|
3
Stoke Therapeutics
STOK
$1.84B
| $136M | 8.98% |
4,164,120
+130,050
| +3% | +$4.27M |
|
4
Immunome
IMNM
$2.55B
| $122M | 8.05% |
5,558,885
-159,500
| -3% | -$3.55M |
|
|
5
Nurix Therapeutics
NRIX
$2.43B
| $120M | 7.94% |
7,732,808
-361,100
| -4% | -$5.99M |
|
|
6
Annexon
ANNX
$927M
| $80.6M | 5.34% |
14,549,768
+4,499,124
| +45% | +$25.3M |
|
7
ADC Therapeutics
ADCT
$158M
| $58M | 3.84% |
15,470,502
-196,229
| -1% | -$774K |
|
8
Regenxbio
RGNX
$614M
| $36.6M | 2.42% |
4,368,804
| – | – |
|
9
Shattuck Labs
STTK
$623M
| $35.6M | 2.36% |
5,539,724
| – | – |
|
10
Beam Therapeutics
BEAM
$3.15B
| $29.5M | 1.95% |
1,237,659
-48,200
| -4% | -$1.34M |
|
11
Neurogene
NGNE
$784M
| $29.4M | 1.95% |
1,459,599
| – | – |
|
|
12
Cogent Biosciences
COGT
$6.68B
| $26.5M | 1.75% |
688,036
-749,882
| -52% | -$27.7M |
|
13
Absci
ABSI
$1.71B
| $24.8M | 1.64% |
8,253,316
| – | – |
|
|
14
IDEAYA Biosciences
IDYA
$3.53B
| $17.4M | 1.15% |
521,117
-220,900
| -30% | -$7.41M |
|
|
15
ALX Oncology
ALXO
$269M
| $16M | 1.06% |
7,964,188
+4,699,470
| +144% | +$8.95M |
|
16
Fate Therapeutics
FATE
$346M
| $15.4M | 1.02% |
12,872,946
| – | – |
|
17
Xenon Pharmaceuticals
XENE
$6.49B
| $15.3M | 1.01% |
262,674
+128,792
| +96% | +$5.93M |
|
18
Solid Biosciences
SLDB
$928M
| $14.5M | 0.96% |
2,011,895
+151,353
| +8% | +$973K |
|
19
Nuvation Bio
NUVB
$2.04B
| $13.5M | 0.9% |
3,153,256
-10,000
| -0.3% | -$55.7K |
|
20
Zymeworks
ZYME
$1.82B
| $12.3M | 0.82% |
491,654
| – | – |
|
|
SLN
21
Silence Therapeutics
SLN
$479M
| $11.4M | 0.76% |
2,164,777
| – | – |
|
|
DBVT
22
DBV Technologies
DBVT
$921M
| $10.3M | 0.68% |
491,340
-58,500
| -11% | -$1.22M |
|
|
23
BioMarin Pharmaceuticals
BMRN
$11.4B
| $9.82M | 0.65% |
+173,859
| New | +$10.1M |
|
24
Celldex Therapeutics
CLDX
$2.99B
| $8.3M | 0.55% |
261,508
-21,800
| -8% | -$594K |
|
|
CBLL
25
CeriBell Inc
CBLL
$747M
| $7.09M | 0.47% |
386,786
-48,453
| -11% | -$974K |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO